Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | 3004081 | PO / MO |
The patient took three doses of Vivotif which expired on 28-Feb-2025; Case reference number US-BN-2025-000893 is a spontaneous case initially received from a nurse via Communication (reference number: USBAV25-0982) on 30-Apr-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 24-Apr-2025, the patient took the first dose of Vivotif (batch number: 3004081; expiration date: 28-Feb-2025) orally, at unknown dose, for indication typhoid prophylaxis, patient was traveling to (withheld). The expiration date was February 28th of this year (explicitly coded as 'expired vaccine used'). On 26-Apr-2025, two days after the first dose, the patient took the second dose of Vivotif (batch number: 300408; expiration date: 28-Feb-2025)) orally, at unknown dose. On 28-Apr-2025, four days after the first dose, the patient took the third dose of Vivotif (batch number: 300408; expiration date: 28-Feb-2025)) orally, at unknown dose. At the time of initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age took Vivotif which had expired. The expiration date was 28-Fe-2025 and the patient took first dose on 24-Apr-2025 which is considered as expired vaccine used. The patient took three doses of Vivotif which expired on 28-Feb-2025. Expired product administered is considered listed per company convention. At this point, it was unknown if the patient experienced any of adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Expired product administered is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age took Vivotif which had expired. The expiration date was 28-Fe-2025 and the patient took first dose on 24-Apr-2025 which is considered as expired vaccine used. The patient took three doses of Vivotif which expired on 28-Feb-2025. Expired product administered is considered listed per company convention. At this point, it was unknown if the patient experienced any of adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Expired product administered is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: NONE